Klinik und Therapie des diabetischen Makulaödems

Einleitung

Die diabetische Retinopathie ist die häufigste Folgeerkrankung des Diabetes mellitus. Es kommt zu einer progredienten Schädigung der Netzhaut im Sinne einer Mikroangiopathie. In Industrieländern ist die diabetische Retinopathie trotz aller Bemühungen noch immer die häufigste Ursache für erhebliche Sehbehinderung oder Erblindung im Erwachsenenalter.

Literatur

• 1 Lang G E. Diabetische Retinopathie – Stadieneinteilung und Laserbehandlung.  Klin Monatsbl Augenheilkd. 2005;  222 R1-R18
• 2 Klein R. The Epidemiology of diabetic Retinopathy.. In: Duh E Diabetic Retinopathy.. Humana Press; 2008: 67-107
• 3 Kempen J H, O'Calmain B J, Leske M C et al. The prevalence of diabetic retinopathy among adults in the United States.  Arch Ophthalmol. 2004;  122 552-563
• 4 Klein R, Klein B E, Moss S E et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years.  Arch Ophthalmol. 1984;  102 520-526
• 5 Klein R, Klein B E, Moss S E et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years.  Arch Ophthalmol. 1984;  102 527-532
• 6 Hirai F E, Knudtson M D, Klein B E et al. Clinically significant macular edema and survival in type 1 and type 2 diabetes.  Am J Ophthalmol. 2008;  145 700-706
• 7 Klein R, Knudtson M D, Lee K E et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII. The twenty-five-year incidence of macular edema in persons with type 1 diabetes.  Ophthalmology. 2009;  116 497-503
• 8 Swenarchuk L E, Whetter E, Adamis A P. The Role of Inflammation in the Pathophysiology of diabetic Retinopathy.. In: Duh E Diabetic Retinopathy.. Humana Press; 2008: 303-332
• 9 Caldwell R B, Bartoli M, Behzadian M A et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives.  Diabetes Metab Res Rev. 2003;  19 442-445
• 10 Lang G E. Optical coherence tomography findings in diabetic retinopathy.  Dev Ophthalmol. 2007;  39 31-47
• 11 Joussen A M, Smyth N, Niessen C. Pathophysiology of diabetic macular edema.  Dev Ophthalmol. 2007;  39 1-12
• 12 Deissler H, Lang G E. Wirkung von VEGF165 und dem VEGF-Aptamer Pegaptanib (Macugen®) auf die Zusammensetzung der Tight Junctions mikrovaskulärer Endothelzellen der Retina.  Klin Monatsbl Augenheilk. 2008;  225 863-867
• 13 Lang G E. Laser treatment of diabetic retinopathy.  Dev Ophthalmol. 2007;  39 48-68
• 14 Early Treatment Diabetic Retinopathy Study Group . Photocoagulation for diabetic macular edema. ETDRS report no 1.  Arch Ophthalmol. 1985;  91 1795-1806
• 15 Diabetic Retinopathy Clinical Research Network . A randomized trial comparing intravitreal triamcinolone acteonide and focal/grid photocoagulation in diabetic macular edema.  Ophthalmology. 2008;  115 1447-1450
• 16 Diabetic Retinopathy Clinical Research Network . Comparison of modified-ETDRS and mild macular grid laser photocoagulation strategies for diabetic macular edema.  Arch Ophthalmol. 2007;  125 469-480
• 17 Diabetic Retinopathy Study Group . Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of diabetic retinopathy study findings. DRS report no 8.  Ophthalmology. 1981;  88 583
• 18 Scott I U, Danis R P, Bressler S B et al. for the DRCRnetwork.. Effekt of focal/grid photocoagulation on visual acuity and retinal thickening in eyes with non-center involved clinically significant diabetic macular edema.  Retina. 2009;  29 613-617
• 19 Diabetic Retinopathy Clinical Research Network . Three year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitral triamcinolone for diabetic macular edema.  Arch Ophthalmol. 2009;  127 245-251
• 20 Gandorfer A. Diffuse diabetic macular edema: pathology and implications for surgery.  Dev Ophthalmol. 2007;  39 88-95
• 21 Joussen A M. Benefits and limitations in vitreoretinal surgery for proliferative diabetic retinopathy and macular edema.  Dev Ophthalmol. 2007;  39 69-87
• 22 Jonas J B. Intravitreal triamcinolone acetonide for diabetic retinopathy.  Dev Ophthalmol. 2007;  39 96-110
• 23 Gerding H, Hefner L, Riese J et al. Fokale Laserkoagulation des diabetischen Makulaödems nach vorbereitender Triamcinolon-Injektion: Ergebnisse nach 6 Monaten.  Klin Monatsbl Augenheilkd. 2010;  227 249-251
• 24 Pearson P Fluocinolone Acetonide Implant Study Group et al. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema.  Invest Ophthalmol Vis Sci. 2006;  47 E-Abstract 5442
• 25 Champochiaro P A, Hafiz G, Shah S M Famous Study Group et al. Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert.  Ophthalmology. 2010;  117 1393-1399
• 26 Do D V, Haller J A et al. Anti-VEGF Therapy as emerging Treatment for diabetic Retinopathy.. In: Duh E Diabetic Retinopathy.. Humana Press; 2008: 401-421
• 27 Kakkassery V, Winterhalter S, Joussen A M. Die Rolle der Anti-VEGF-Therapie in der Behandlung des diabetischen Makulaödems.  Klin Mbl Augenheilkd. 2010;  227 701-711
• 28 Ferrara N. Vascular endothelial growth factor: Basic Science and Clinical Progress.  Endocrine Reviews. 2004;  25 581-611
• 29 Starita C, Patel M, Katz B et al. Vascular endothelial growth factor and the potential therapeutic use of pegaptanib (Macugen) in diabetic retinopathy.  Dev Ophthalmol. 2007;  39 122-148
• 30 Deissler H L, Lang G E. In vitro-Untersuchungen zum Wirkungsmechanismus von VEGF und seinen Inhibitoren.  Klin Monatsbl Augenheilk. 2008;  225 623-628
• 31 Deissler H, Deissler H, Lang S et al. VEGF-induced effects on proliferation, migration and tight junctions are restored by ranibizumab (Lucentis®) in microvascular retinal endothelial cells.  Br J Ophthalmol. 2008;  92 839-843
• 32 Mendrinos E, Donati G, Pournaras C J. Rapid and persistent regression of severe new vessels on the disc in proliferative diabetic retinopathy after a single intravitreal injection of pegaptanib.  Acta Ophthalmol. 2009;  87 683-684
• 33 Cunningham Jr. E T, Adamis A P, Altaweel M Macugen Diabetic Study Group et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.  Opthalmology. 2005;  112 1747-1757
• 34 Adamis A P, Altaweel M, Bressler N M Macugen Diabetic Retinopathy Study Group et al. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals.  Ophthalmology. 2006;  113 23-28
• 35 Chun D W, Heier J S, Topping T M et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema.  Ophthalmology. 2006;  113 1706-1712
• 36 Nguyen Q D, Shah S M, Khwaja A A et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) Study.  Ophthalmology. 2010;  117 2146-2151
• 37 Massin P, Bandello F, Garweg J G et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month randomized, controlled, double-masked, multicenter phase II study.  Diabetes Care. 2010;  33 2399-2405
• 38 Mitchell P et al. Efficacy and safety of intravitreal ranibizumab as adjunctive therapy to laser photocoagulation or as monotherapy in diabetic macular edema: 12-month results from the RESTORE study. Berlin; World Ophthalmology Congress 2010: Abstract WE-38-02
• 39 The Diabetic Retinopathy Clinical Research Network . Randomized trial evaluation ranibizumab plus prompt or deferred laser or triamconolone plus prompt laser for diabetic macular edema.  Ophthalmology. 2010;  117 1064-1077
• 40 Isaacs T W, Barry C. Rapid resolution of severe disc new vessels in proliferative diabetic retinopathy following a single intravitreal injection of bevacizumab (Avastin).  Clin Experiment Ophthalmol. 2006;  34 802-803
• 41 Avery R L, Pearlman J, Pieramici D J et al. Intravitreal bevacizumab (Avastin®) in the treatment of proliferative diabetic retinopathy.  Ophthalmology. 2006;  113 1695.e1-e15
• 42 Grisanti S, Biester S, Peters S Tuebingen Bevacizumab Study Group et al. Intracameral bevacizumab for iris rubeosis.  Am J Ophthalmol. 2006;  142 158-160
• 43 Chalam K V, Gupta S K, Grover S et al. Intracameral Avastin dramatically resolves iris neovascularization and reverses neovascular glaucoma.  Eur J Ophthalmol. 2008;  18 255-262
• 44 Minnella A M, Savastano C M, Ziccardi L et al. Intravitreal bevacizumab (Avastin) in proliferative diabetic retinopathy.  Acta Ophthalmol. 2008;  86 683-687
• 45 Spaide R F, Fisher Y L. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.  Retina. 2006;  26 275-278
• 46 Scott I U, Edwards A R, Beck R W Diabetic Retinopathy Clinical Research Network et al. A phase 2 randomized clinical trial of intravitreal bevacizumab for diabetic macular edema.  Ophthalmology. 2007;  114 1860-1867
• 47 Michaelides M, Kaines A, Hamilton R D et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2.  Ophthalmology. 2010;  117 1078-1086